DPK 060

Drug Profile

DPK 060

Alternative Names: DPK-060

Latest Information Update: 26 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DermaGen
  • Developer DermaGen; Pergamum
  • Class Antimicrobial cationic peptides
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Atopic dermatitis; Otitis externa

Most Recent Events

  • 14 Nov 2017 Promore Pharma out-licenses DPK 060 to Transdermal Therapeutic Technologies in USA
  • 02 Oct 2015 No recent reports of development identified - Phase-II for Otitis externa in Sweden (Topical)
  • 31 Dec 2012 Top-line efficacy and tolerability data from a phase II trial in Otitis externa released by Karolinska Development and Pergamum
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top